About Us
- Design and conduct pre-clinical and clinical studies in breast and colorectal cancer to improve treatment and advance the standard of care.
- Learn about the heritage, expertise and vision that drives us forward every day.
  Learn More
- Meet the experts leading our organization in the pursuit of The Mission.
  Meet the Experts
- Read the latest announcements and press releases, or search our media library.
  Read the Latest
Our Network
- We leverage our expertise through close collaboration across our network to prove the efficacy of new cancer treatments.
- Thousands of sites facilitate trials by recruiting participants, administering treatments, and reporting results.
  View Sites
- Links to NCI National Clinical Trials Network along with Industry Partners and other Government Agencies.
  View Links
Patient Resources
Clinical Trials
Log In
- Visitors who have already been issued credentials must log in to access protected content.
  Log In
- Individuals working for sites that participate in NSABP clinical trials.
  Register Now
Support Our Mission

Clinical Trial Detailsnsabpwordpress2021-02-22T09:37:43-05:00

NSABP FC-11

Overview

Overview

NSABP FC-11

A Phase II Study Evaluating the Combination of Neratinib Plus Trastuzumab or Neratinib Plus Cetuximab in Patients with "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Based on HER2 Status: Amplified, Non-Amplified (Wild-Type) or Mutated

Protocol Chair: Shannon Puhalla, MD

Protocol Officer: Carmen Allegra, MD

Patient Population:
Patients with KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer

Target Accrual: 35 patients

Status: Active, Not Recruiting

ClinicialTrials.gov Identifier: NCT03457896

NSABP FC-11

Overview

Overview